- Home
- EDF vs VTVT Comparison
EDF vs VTVT Comparison
Compare EDF & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | VTVT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 148.7M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EDF | VTVT |
|---|---|---|
| Price | $5.11 | $30.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | ★ 146.3K | 70.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.72 | $14.00 |
| 52 Week High | $5.67 | $44.00 |
Technical Indicators
Market Signals| Indicator | EDF | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 38.91 |
| Support Level | $4.81 | $30.13 |
| Resistance Level | $5.19 | $33.76 |
| Average True Range (ATR) | 0.10 | 2.15 |
| MACD | -0.04 | -0.28 |
| Stochastic Oscillator | 6.19 | 7.85 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.